Loading...
Loading...
Orexigen® Therapeutics, Inc.
, a biopharmaceutical company focused on the treatment of obesity, today
provided a clinical trial update of the Light Study as well as results of
recent market research at its Analyst Day meeting in New York City. Orexigen
reported that the screening of new patients for the Light Study, the
cardiovascular outcomes trial evaluating Contrave® (Naltrexone SR/Bupropion
SR), is now complete. Approximately 9,000 patients will be randomized in the
study within the next few weeks. An interim analysis of the Light Study will
occur after approximately 87 major adverse cardiovascular events (MACE) are
accrued in the study. Although it is still too early to predict the rate of
MACE, if the annual rate is close to the target of 1.5%, Orexigen anticipates
resubmitting the Contrave New Drug Application and conducting the interim
analysis in 2013, with potential approval as early as fourth quarter 2013.
"With great performance from our clinical sites and with the help of our
partners, including Blue Chip Marketing Worldwide, the Orexigen team deployed
several innovative strategies and tactics to enroll the Light Study in just
six and a half months," said Michael Narachi, CEO of Orexigen. "We now look
forward to 2013, when we anticipate being able to provide interim data from
the Light Study to the FDA and CHMP for review and potential approval in the
US and Europe."
Today the Company also discussed recent physician and patient market research
which was conducted to assess potential growth of the obesity therapeutics
market as well as preference shares between Contrave® and two recently
approved obesity therapeutics. The quantitative market research conducted with
1,000 physicians suggests the market for obesity therapeutics could grow 3 to
4 fold within five years from a 2012 base of approximately 7.8 million
prescriptions. The physician research also suggests that Contrave, if
approved, would be perceived favorably among the new product entrants. This
was especially true among certain important patient profiles that included
some or all of the following characteristics: female; a body mass index
between 30 and 40; and diabetes.
The Company conducted another market research study that surveyed more than
5,000 patients to assess interest levels between Contrave and the same two
recently approved obesity therapeutics. The results of this research indicate
attractive levels of patient interest for Contrave, especially across certain
important segments of the obese and overweight patient population, supporting
the physician research findings.
"Our extensive market research demonstrates the potential for the obesity
therapeutics market to grow 3 to 4 fold in the next few years as multiple new
drugs with different mechanisms of action become available, giving prescribers
and patients new tools to fight obesity," said Mark Booth, Chief Commercial
Officer of Orexigen. "We were also pleased with how Contrave performed in this
research across the most important patient demographic segments."
The webcast of the Analyst Day presentations can be accessed live on the
Investor Relations section of the Orexigen website at www.orexigen.com and
will be archived for 14 days following the Analyst Day.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in